Claudia Angela Maria Fulgenzi
A5051093023- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Hepatitis C virus research
- Colorectal Cancer Treatments and Studies
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- Cancer Mechanisms and Therapy
- Inflammatory Biomarkers in Disease Prognosis
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Cancer, Lipids, and Metabolism
- Hepatitis B Virus Studies
- COVID-19 and healthcare impacts
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease and Transplantation
- Immune cells in cancer
- Liver physiology and pathology
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
Imperial College London
2021-2025
Hammersmith Hospital
2021-2025
Università Campus Bio-Medico
2020-2024
European Organisation for Research and Treatment of Cancer
2024
Campus Bio Medico University Hospital
2020-2023
Imperial College Healthcare NHS Trust
2023
University of Zurich
2022
Centre de Recherche sur l'Inflammation
2022
Université Paris Cité
2022
Inserm
2022
Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment unresectable HCC. No evidence exists as to its use in routine clinical practice patients with impaired liver function.
Importance Currently, predictive biomarkers for response to immune checkpoint inhibitor (ICI) therapy in lung cancer are limited. Identifying such would be useful refine patient selection and guide precision therapy. Objective To develop a machine-learning (ML)-based tumor-infiltrating lymphocytes (TILs) scoring approach, evaluate TIL association with clinical outcomes patients advanced non–small cell (NSCLC). Design, Setting, Participants This multicenter retrospective discovery-validation...
Direct comparisons across first-line regimens for advanced hepatocellular carcinoma are not available. We performed a network metanalysis of phase III trials to compare systemic treatments in terms overall survival (OS), progression-free (PFS), objective response rate, disease control and incidence adverse events (AEs).
Systemic inflammation is a hallmark of cancer, and it has pivotal role in hepatocellular carcinoma (HCC) development progression. We conducted retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence neutrophiles to lymphocytes ratio (NLR), platelets (PLR), prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), radiologic responses. In our treated with immunotherapy, median OS PFS...
Importance Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced hepatocellular carcinoma (HCC). However, data on ICI therapy HCC and impaired liver function scarce. Objective To conduct a systematic review meta-analysis to determine the efficacy safety of treatment for Child-Pugh B function. Data Sources PubMed, Embase, Web Science, Cochrane Library were searched relevant studies from inception through June 15, 2022. Study Selection Randomized clinical trials,...
Immune-related liver injury (irLI) is commonly observed in patients with cancer treated immune checkpoint inhibitors (ICIs). We aimed to compare the incidence, clinical characteristics, and outcomes of irLI between receiving ICIs for hepatocellular carcinoma (HCC) vs. other solid tumours.
Transarterial chemoembolization (TACE) may prime adaptive immunity and enhance immunotherapy efficacy. PETAL evaluated safety, preliminary activity of TACE plus pembrolizumab explored mechanisms
Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy real-life use Atezo/Bev HCC.191 consecutive patients from seven centres receiving were included retrospective study. Overall survival (OS), progression-free (PFS), overall rate (ORR) disease control (DCR)...
Background and Aims: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, relative contribution decompensation over influencing overall survival (OS) has not been assessed combination immunotherapy recipients. Approach Results: From AB-real observational study (n = 898), we accrued 571 patients advanced/unresectable carcinoma, Child-Pugh A class treated frontline atezolizumab +...
Background The determinants of the response to checkpoint immunotherapy in hepatocellular carcinoma (HCC) remain poorly understood. organisation immune tumour microenvironment (TME) is expected govern outcomes but spatial immunotypes defined. Objective We hypothesised that deconvolution network architectures could identify clinically relevant HCC. Design conducted highly multiplexed imaging mass cytometry on HCC tissues from 101 patients. performed in-depth single-cell analysis a discovery...
Lenvatinib has been approved in Italy since October 2019 as a first-line therapy for advanced hepatocellular carcinoma (HCC) and to date data on effectiveness safety of lenvatinib are not available our region. To fill this gap, we performed multicentric analysis the real-world treatment outcomes with propensity score matching cohort Italian patients unresectable HCC who were treated either sorafenib or lenvatinib.To evaluate primary clinical practice 288 such recruited 11 centers Italy. A...
Combination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated efficacy and safety combination therapy in older patients with HCC.
Different approaches are available after the progression of disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC), including continuation ICI, treatment switching tyrosine kinase (TKIs) and cessation anticancer therapy. We sought characterise relationship between radiological patterns survival post-ICI, also appraising strategies.
Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients various malignancies including non-small cell lung cancer (NSCLC). However, it unclear whether baseline BMI may influence outcomes first-line chemoimmunotherapy combinations. Methods In this international multicenter study, we evaluated the association between BMI, progression-free survival (PFS) and overall (OS) a cohort of stage...
While deemed potentially curative, surgical resection of hepatocellular carcinoma (HCC) is associated with >70% risk post-operative relapse. Recurrence uniquely multifactorial in HCC, stemming from metachronous re-occurrence the original tumor or de novo cancerization. Circulating DNA may improve personalized stratification post-resection, a setting where adjuvant immunotherapy has failed to provide survival benefits.